CCP
AKRO

Clough Capital Partners’s Akero Therapeutics AKRO Stock Holding History

Clough Capital Partners’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-72,200
Closed -$3.65M – 196
2023
Q3 		$3.65M Buy
+72,200
New +$3.36M 0.39% 69

Other funds holding AKRO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clough Capital Partners's AKRO Position: Q4 2023 in Review

Clough Capital Partners sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 72,200 shares — an estimated $3.65M sold.

Clough Capital Partners first reported a position in AKRO in Q3 2023 and held it in 1 quarter. The position peaked at $3.65M in Q3 2023. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

  • Clough Capital Partners reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Clough Capital Partners sold 72,200 Akero Therapeutics shares in Q4 2023, an estimated $3.65M.
  • Clough Capital Partners first reported a position in Akero Therapeutics in Q3 2023 and held it in 1 quarter.
  • Clough Capital Partners's Akero Therapeutics position peaked at $3.65M in Q3 2023.
  • 157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on Clough Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.